nach oben

Erschienen in:

24.11.2017 | Gynecologic Endocrinology and Reproductive Medicine

Hyperandrogenemia and ovarian reserve in patients with Mayer–Rokitansky–Küster–Hauser syndrome type 1 and 2: potential influences on ovarian stimulation

verfasst von: Melanie Henes, Ludmila Jurow, Andreas Peter, Birgitt Schoenfisch, Florin Andrei Taran, Markus Huebner, Harald Seeger, Sara Yvonne Brucker, Kristin Katharina Rall

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to analyze the hormone profiles, to detect the rate of hyperandrogenemia and to investigate the potential effect of Mayer–Rokitansky–Küster–Hauser syndrome (MRKHS) on ovarian reserve, as reflected by the serum Anti-Mullerian hormone (AMH) levels. Clinical implications were analyzed by including our own experiences with three patients after ovarian stimulation in preparation for uterus transplantation.

Methods

Serum samples of 100 patients with MRKHS (50 patients with MRKHS type 1 and 50 with type 2) were analyzed and compared to 50 individually age-matched healthy controls. Blood samples for hormone analyses were collected routinely during the clinical visit.

Results

The mean age was 20.0 years for MRKHS type 1, MRKHS type 2 and healthy controls. Compared to healthy controls, there was no significant difference in AMH values in the MRKH patients. As shown in previous studies, the proportion of hyperandrogenemia without clinical symptoms was significantly higher in MRKHS type 1 (52%; p < 0.001) and type 2 (56%; p < 0.001) patients when compared to age-matched controls. In preparation for uterus transplantation, three patients were stimulated with FSH/hMG for mean 14.2 days and the mean number of aspirated oocytes was 13.2 (3–22), while 8.3 (2–10) oocytes could be fertilized and cryopreserved. The mean fertilization rate was 51.2% (30–67%).

Conclusion

The rate of hyperandrogenemia was significantly higher in MRKH patients compared to healthy age-matched controls. Though, ovarian reserve (AMH level) was not reduced compared to controls. Future studies are needed to identify optimal ovarian stimulation protocols as well as to implement a systematic multicenter reporting system.

Aittomaki K, Eroila H, Kajanoja P (2001) A population-based study of the incidence of Mullerian aplasia in Finland. Fertil Steril 76:624–625CrossRefPubMed

Anonymous (2016) Deutsches IVF Register (DIR), Jahrbuch 2015. modif. Reprint from J Reproduktionsmed Endokrinol 13

Balen A (2004) The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol 18:685–706CrossRefPubMed

Bernardini L, Gimelli S, Gervasini C et al (2009) Recurrent microdeletion at 17q12 as a cause of Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome: two case reports. Orphanet J Rare Dis 4:25CrossRefPubMedPubMedCentral

Biason-Lauber A, De Filippo G, Konrad D et al (2007) WNT4 deficiency–a clinical phenotype distinct from the classic Mayer-Rokitansky-Kuster-Hauser syndrome: a case report. Hum Reprod 22:224–229CrossRefPubMed

Biason-Lauber A, Konrad D, Navratil F et al (2004) A WNT4 mutation associated with Mullerian-duct regression and virilization in a 46, XX woman. N Engl J Med 351:792–798CrossRefPubMed

Brannstrom M, Bokstrom H, Dahm-Kahler P et al (2016) One uterus bridging three generations: first live birth after mother-to-daughter uterus transplantation. Fertil Steril 106:261–266CrossRefPubMed

Brannstrom M, Johannesson L, Bokstrom H et al (2015) Livebirth after uterus transplantation. Lancet 385:607–616CrossRefPubMed

10.

Brucker SY, Gegusch M, Zubke W et al (2008) Neovagina creation in vaginal agenesis: development of a new laparoscopic Vecchietti-based procedure and optimized instruments in a prospective comparative interventional study in 101 patients. Fertil Steril 90:1940–1952CrossRefPubMed

11.

Carranza-Lira S, Forbin K, Martinez-Chequer JC (1999) Rokitansky syndrome and MURCS association—clinical features and basis for diagnosis. Int J Fertil Womens Med 44:250–255PubMed

12.

Chen MJ, Wei SY, Yang WS et al (2015) Concurrent exome-targeted next-generation sequencing and single nucleotide polymorphism array to identify the causative genetic aberrations of isolated Mayer-Rokitansky-Kuster-Hauser syndrome. Hum Reprod 30:1732–1742CrossRefPubMed

13.

Cicinelli E, Einer-Jensen N, Cignarelli M et al (2004) Preferential transfer of endogenous ovarian steroid hormones to the uterus during both the follicular and luteal phases. Hum Reprod 19:2001–2004CrossRefPubMed

14.

Folch M, Pigem I, Konje JC (2000) Mullerian agenesis: etiology, diagnosis, and management. Obstet Gynecol Surv 55:644–649CrossRefPubMed

15.

Fraser IS, Baird DT, Hobson BM et al (1973) Cyclical ovarian function in women with congenital absence of the uterus and vagina. J Clin Endocrinol Metab 36:634–637CrossRefPubMed

16.

Friedler S, Grin L, Liberti G et al (2016) The reproductive potential of patients with Mayer-Rokitansky-Kuster-Hauser syndrome using gestational surrogacy: a systematic review. Reprod Biomed Online 32:54–61CrossRefPubMed

17.

Hall-Craggs MA, Kirkham A, Creighton SM (2013) Renal and urological abnormalities occurring with Mullerian anomalies. J Pediatr Urol 9:27–32CrossRefPubMed

18.

Hansen KR, Knowlton NS, Thyer AC et al (2008) A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum Reprod 23:699–708CrossRefPubMed

19.

Herlin M, Bjorn AM, Rasmussen M et al (2016) Prevalence and patient characteristics of Mayer-Rokitansky-Kuster-Hauser syndrome: a nationwide registry-based study. Hum Reprod 31:2384–2390CrossRefPubMed

20.

Jb B (1959) Preliminary observation on urinary oestrogen excretion in certain gynaecological disorders. J Obstet Gynaecol Br Commonw 66:177–211CrossRef

21.

Kallio S, Puurunen J, Ruokonen A et al (2013) Antimullerian hormone levels decrease in women using combined contraception independently of administration route. Fertil Steril 99:1305–1310CrossRefPubMed

22.

Kim JY, Tfayli H, Michaliszyn SF et al (2017) Anti-Mullerian Hormone in Obese Adolescent Girls With Polycystic Ovary Syndrome. J Adolesc Health 60:333–339CrossRefPubMed

23.

Ledig S, Schippert C, Strick R et al (2011) Recurrent aberrations identified by array-CGH in patients with Mayer-Rokitansky-Kuster-Hauser syndrome. Fertil Steril 95:1589–1594CrossRefPubMed

24.

Morcel K, Watrin T, Pasquier L et al (2011) Utero-vaginal aplasia (Mayer-Rokitansky-Kuster-Hauser syndrome) associated with deletions in known DiGeorge or DiGeorge-like loci. Orphanet J Rare Dis 6:9CrossRefPubMedPubMedCentral

25.

Nik-Zainal S, Strick R, Storer M et al (2011) High incidence of recurrent copy number variants in patients with isolated and syndromic Mullerian aplasia. J Med Genet 48:197–204CrossRefPubMedPubMedCentral

26.

Oppelt P, Renner SP, Kellermann A et al (2006) Clinical aspects of Mayer-Rokitansky-Kuester-Hauser syndrome: recommendations for clinical diagnosis and staging. Hum Reprod 21:792–797CrossRefPubMed

27.

Oppelt P, Strissel PL, Kellermann A et al (2005) DNA sequence variations of the entire anti-Mullerian hormone (AMH) gene promoter and AMH protein expression in patients with the Mayer-Rokitanski-Kuster-Hauser syndrome. Hum Reprod 20:149–157CrossRefPubMed

28.

Oppelt PG, Mueller A, Stephan L et al. (2017) Hyperandrogenemia and high prolactin in congenital utero-vaginal aplasia patients. Reproduction

29.

Ozekinci M, Erman Akar M, Senol Y et al (2015) Comparison of markers of ovarian reserve between patients with complete mullerian agenesis and age-matched fertile and infertile controls. Fertil Steril 104:176–179CrossRefPubMed

30.

Philibert P, Biason-Lauber A, Gueorguieva I et al (2011) Molecular analysis of WNT4 gene in four adolescent girls with mullerian duct abnormality and hyperandrogenism (atypical Mayer-Rokitansky-Kuster-Hauser syndrome). Fertil Steril 95:2683–2686CrossRefPubMed

31.

Philibert P, Biason-Lauber A, Rouzier R et al (2008) Identification and functional analysis of a new WNT4 gene mutation among 28 adolescent girls with primary amenorrhea and mullerian duct abnormalities: a French collaborative study. J Clin Endocrinol Metab 93:895–900CrossRefPubMed

32.

Rall K, Conzelmann G, Schaffeler N et al (2014) Acne and PCOS are less frequent in women with Mayer-Rokitansky-Kuster-Hauser syndrome despite a high rate of hyperandrogenemia: a cross-sectional study. Reprod Biol Endocrinol 12:23CrossRefPubMedPubMedCentral

33.

Raziel A, Friedler S, Gidoni Y et al (2012) Surrogate in vitro fertilization outcome in typical and atypical forms of Mayer-Rokitansky-Kuster-Hauser syndrome. Hum Reprod 27:126–130CrossRefPubMed

34.

Sandbacka M, Halttunen M, Jokimaa V et al (2011) Evaluation of SHOX copy number variations in patients with Mullerian aplasia. Orphanet J Rare Dis 6:53CrossRefPubMedPubMedCentral

35.

Sowers M, Mcconnell D, Gast K et al (2010) Anti-Mullerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril 94:1482–1486CrossRefPubMed

36.

Strissel PL, Oppelt P, Cupisti S et al (2009) Assessment of pituitary and steroid hormones and members of the TGF-beta superfamily for ovarian function in patients with congenital uterus and vaginal aplasia (MRKH syndrome). Horm Metab Res 41:408–413CrossRefPubMed

37.

Strubbe EH, Willemsen WN, Lemmens JA et al (1993) Mayer-Rokitansky-Kuster-Hauser syndrome: distinction between two forms based on excretory urographic, sonographic, and laparoscopic findings. AJR Am J Roentgenol 160:331–334CrossRefPubMed

38.

Sultan C, Biason-Lauber A, Philibert P (2009) Mayer-Rokitansky-Kuster-Hauser syndrome: recent clinical and genetic findings. Gynecol Endocrinol 25:8–11CrossRefPubMed

39.

Ugur M, Karakaya S, Zorlu G et al (1995) Polycystic ovaries in association with mullerian anomalies. Eur J Obstet Gynecol Reprod Biol 62:57–59CrossRefPubMed

40.

Verma AK, Rajbhar S, Mishra J et al (2016) Anti-mullerian hormone: a marker of ovarian reserve and its association with polycystic ovarian syndrome. J Clin Diagn Res 10:QC10–QC12PubMedPubMedCentral

41.

Visser JA, De Jong FH, Laven JS et al (2006) Anti-Mullerian hormone: a new marker for ovarian function. Reproduction 131:1–9CrossRefPubMed

Titel: Hyperandrogenemia and ovarian reserve in patients with Mayer–Rokitansky–Küster–Hauser syndrome type 1 and 2: potential influences on ovarian stimulation
verfasst von: Melanie Henes
Ludmila Jurow
Andreas Peter
Birgitt Schoenfisch
Florin Andrei Taran
Markus Huebner
Harald Seeger
Sara Yvonne Brucker
Kristin Katharina Rall
Publikationsdatum: 24.11.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2018
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-017-4596-1

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Hyperandrogenemia and ovarian reserve in patients with Mayer–Rokitansky–Küster–Hauser syndrome type 1 and 2: potential influences on ovarian stimulation

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Vacuum extraction in low birth weight (< 2500 g) neonates

RASSF1A promoter methylation was associated with the development, progression and metastasis of cervical carcinoma: a meta-analysis with trial sequential analysis

Laparoscopic-assisted vaginal hysterectomy versus vaginal hysterectomy for benign uterine diseases: a prospective, randomized, multicenter, double-blind trial (LAVA)

MicroRNA-21 promotes proliferation, migration, and invasion of cervical cancer through targeting TIMP3

Clinical effect of emergency cervical cerclage and elective cervical cerclage on pregnancy outcome in the cervical-incompetent pregnant women

Effect of intramural fibroid on uterine and endometrial vascularity in infertile women scheduled for in-vitro fertilization

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie